Literature DB >> 9662143

Bidirectional modulation of AMPA receptor properties by exogenous phospholipase A2 in the hippocampus.

C Chabot1, J Gagné, C Giguère, J Bernard, M Baudry, G Massicotte.   

Abstract

The synaptic modifications underlying long-term potentiation (LTP) and long-term depression (LTD) of synaptic transmission in various brain structures may result from changes in the properties of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of glutamate receptors. In the present study, we report that treatment of rat synaptoneurosomes with increasing concentrations of phospholipase A2 (PLA2) produces a biphasic effect on AMPA receptor binding, with low concentrations causing a decrease and high concentrations an increase in agonist binding. Analysis of the saturation kinetics of 3H-AMPA binding revealed that the biphasic effect of PLA2 was due to modifications in receptor affinity and not to changes in the maximum number of binding sites for AMPA receptors. The 12-lipoxygenase inhibitors preferentially reduced PLA2-induced decrease in AMPA binding and treatment of hippocampal synaptoneurosomes with arachidonic acid (AA) or 12-HPETE, the first metabolite generated from the hydrolysis of AA by 12-lipoxygenases, decreased 3H-AMPA binding. Moreover, electrophysiological experiments indicated that the 12-lipoxygenase inhibitor baicalein totally blocked LTD formation in area CA1 of hippocampal slices. The decrease in 3H-AMPA binding elicited by low concentrations of PLA2, as well as the level of LTD, were partially reduced by AA-861, a 5-lipoxygenase inhibitor, while the cyclooxygenase inhibitor indomethacin did not prevent LTD formation or the effects of PLA2 on 3H-AMPA binding. Our results provide evidence for a possible involvement of lipoxygenase metabolites in the regulation of AMPA receptor during synaptic depression. In addition, they strongly support the idea that the same biochemical pathway, i.e., NMDA receptor activation and endogenous PLA2 stimulation, may represent a common mechanism resulting in AMPA receptor alterations for both LTP and LTD formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662143     DOI: 10.1002/(SICI)1098-1063(1998)8:3<299::AID-HIPO11>3.0.CO;2-W

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  12 in total

1.  12-hydroxyeicosatetrenoate (12-HETE) attenuates AMPA receptor-mediated neurotoxicity: evidence for a G-protein-coupled HETE receptor.

Authors:  Aidan J Hampson; Maurizio Grimaldi
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

2.  Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats.

Authors:  E L Schaeffer; W F Gattaz
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 3.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

4.  12/15-Lipoxygenase metabolites of arachidonic acid activate PPARγ: a possible neuroprotective effect in ischemic brain.

Authors:  Li Sun; Yan-Wei Xu; Jing Han; Hao Liang; Ning Wang; Yan Cheng
Journal:  J Lipid Res       Date:  2015-01-20       Impact factor: 5.922

Review 5.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

6.  Conditioning training and retrieval increase phospholipase A(2) activity in the cerebral cortex of rats.

Authors:  E L Schaeffer; L Zorrón Pu; D A M Gagliotti; W F Gattaz
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

Review 7.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

8.  Possible role for interactions between 5-lipoxygenase (5-LOX) and AMPA GluR1 receptors in depression and in antidepressant therapy.

Authors:  Radmila Manev; Danijela Mrazovac; Hari Manev
Journal:  Med Hypotheses       Date:  2007-04-20       Impact factor: 1.538

Review 9.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

10.  5-Lipoxygenase DNA methylation and mRNA content in the brain and heart of young and old mice.

Authors:  Svetlana Dzitoyeva; Marta Imbesi; Louisa W Ng; Hari Manev
Journal:  Neural Plast       Date:  2009-12-13       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.